René Russo, Xilio CEO (Alicia Petitti for Xilio)
October 22, 2021 10:52 AM EDT
Financing

Xilio Ther­a­peu­tics goes pub­lic as bio­phar­ma IPOs rum­ble for­ward in Q4

Paul Schloesser

Associate Editor

It’s been a busy fall on Wall Street — and this week, we’ve got an­oth­er biotech go­ing pub­lic af­ter Ven­tyx yes­ter­day.

Mass­a­chu­setts sol­id-tu­mor biotech Xilio …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA de­tails new 'plat­form tech­nol­o­gy' process that could ac­cel­er­ate cell and gene ther­a­py ap­provals

Com­pa­ny de­vel­op­ing video games for AD­HD an­nounces sale

J&J's ma­jor de­pres­sive dis­or­der drug hits end­points in Phase 3 tri­al

Mer­ck re­turns to lu­cra­tive eye dis­ease mar­ket in up to $3B deal for Eye­Bio

Bio­haven’s au­toim­mune drug dis­ap­points in­vestors in study of healthy vol­un­teers 

sponsored

A nov­el study in­sight an­a­lyt­ics (SIA) method­ol­o­gy im­proves PANSS da­ta qual­i­ty and sig­nal de­tec­tion in a glob­al ...

A service from the Financial Times